Abstract
For many years beta adrenergic receptor blocking drugs have been the primary pharmacologic agents for treating symptomatic patients with hypertrophic cardiomyopathy [1–3]. Although effective, not all patients respond adequately to this type of therapy and many experience unpleasant side effects. Recent studies from our laboratory have demonstrated that verapamil administration to patients with hypertrophic cardiomyopathy reduces left ventricular outflow obstruction [4], increases exercise capacity [5], and reduces subjective symptomatology (see below [5]). Kaltenbach and associates have also reported chronic verapamil administration improves symptoms in patients with hypertrophic cardiomyopathy [6]. In addition, angiographic, electrocardiographic, and echocardiography data have been interpreted as suggesting that verapamil reduces left ventricular muscle mass or ventricular septal thickness in these patients [6, 7]. In the present study, we report the results of continued examination of the clinical effects of verapamil in patients with hypertrophic cardiomyopathy discharged from the hospital on chronic therapy.
This paper has previously been published
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Cohen LS, Braunwald E (1967) Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 35: 847–851
Swan DA, Bell B, Oakley CM, Goodwin J (1971) Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy. Br Heart J 33: 671–685
Adelman AG, Wigle ED, Ranganathan N, Webb GD, Kidd BSL, Bigelow WG, Silver MD (1972) The clinical course in muscular subaortic stenosis: a retrospective and prospective study of 60 hemodynamically proved cases. Ann Intern Med 77: 515–525
Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE (1979) Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 60: 1201–1207
Rosing DR, Kent KM, Maron BJ, Epstein SE (1979) Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 60: 1208–1213
Kaltenbach M, Hopf R, Kober G, Bussman W-D, Keller M, Petersen Y (1979) Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 42: 35–42
Troesch M, Hirzel HO, Jenni R, Kayenbühl HP (1979) Reduction of septal thickness following verapamil in patients with asymmetric septal hypertrophy (Abstr). Circulation [Suppl 2] 60: 11–155
Maron BJ, Epstein SE (1979) Hypertrophic cardiomyopathy: A discussion of nomenclature. Am J Cardiol 43: 1242–1244
Borer JS, Bacharach SL, Green MV, Kent KM, Epstein SE, Johnston GS (1977) Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary artery disease. N Engl J Med 296: 839–844
Henry WL, Clark CE, Epstein SE (1973) Asymmetric septal hypertrophy: Echocardiography identification of the pathognomonic anatomic abnormality of IHSS. Circulation 47: 225–233
Jaouni TM, Leon MB, Rosing DR, Fales HM (1980) Analysis of verapamil in plasma by liquid chromatography. J Chromatogr 182: 473–477
Kaplan EL, Meier P (1958) Non-parametric estimation for incomplete observations. J Am Stat Assoc 53: 457–481
Epstein SE, Henry WL, Clark CE, Roberts WC, Maron BJ, Ferrans VJ, Redwood DR, Morrow AG (1974) Asymmetric septal hypertrophy. Ann Intern Med 81: 650–680
Maron BJ, Merrill WH, Freier PA, Kent KM, Epstein SE, Morrow AG (1978) Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation 57: 1205–1213
Schomerus M, Spiegelhalder B, Stelren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10: 605–612
Maron BJ, Gottdiener JS, Epstein SE (1981) Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A wideangle, twodimensional echocardiographic study of 125 patients. Am J Cardiol 48: 418–428
Singh BN, Ellrodt G, Peter CT (1978) Verapamil: A review of its pharmacological properties and therapeutic use. Drugs 15: 169–197
Shah PM, Adelman AG, Wigle ED, Gobel FL, Burchell HB, Hardarson T, Curiel R, De La Calzada C, Oakley CM, Goodwin JF (1973) The natural (and unnatural) course of hypertrophic obstructive cardiomyopathy. A multicenter study. Circ Res [Suppl II] 24, 25: 179–195
Glancy DL, Shepherd RL, Beiser GD, Epstein SE (1971) The dynamic nature of left ventricular outflow obstruction in idiopathic hypertrophic subaortic stenosis. Ann Intern Med 75: 589–592
Kohlhardt M, Bauer B, Krause H, Fleckenstein A (1972) New selective inhibitors of the transmembrane Ca conductivity in mammalian myocardial fibers. Studies with the voltage clamp technique. Experientia 28: 288–289
Shigenobu K, Schneider JA, Sperelakis N (1974) Verapamil blockade of slow Na+ and Ca++ responses in myocardial cells. J Pharmacol Exp Ther 190: 280–288
Hanrath P, Mathey DG, Kremer P, Sonntag F, Bleifeld W (1980) Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol 45: 1258–1268
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Rosing, D.R. et al. (1982). Long-Term Clinical Effects of Verapamil in Patients with Hypertrophic Cardiomyopathy. In: Kaltenbach, M., Epstein, S.E. (eds) Hypertrophic Cardiomyopathy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-68282-7_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-68282-7_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-68284-1
Online ISBN: 978-3-642-68282-7
eBook Packages: Springer Book Archive